ClinicalTrials.gg
CompletedNCT04585906MP2HUpdated Apr 24, 2025Results posted

My Pathway to Healing

An interventional study of Common Elements Treatment Approach in Suicide; Trauma and Binge Drinking, sponsored by Johns Hopkins Bloomberg School of Public Health. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Primary conditionSuicide(the registry's first term)UnverifiedIs this wrong?Suicide is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

The goal of this project is to test the feasibility and acceptability of a common elements intervention delivered by community mental health workers for adults with a history of adverse childhood experiences. "Common elements" interventions build cognitive, emotional, interpersonal, and behavioral skills to help address trauma-related distress and build resilience. This will be accomplished using a randomized control trial with Apache adults ages 25-65 with recent suicidal behaviors, self-injurious behaviors, and/or binge substance use.

Read the detailed description

This is a mixed-methods study with qualitative data informing adaptation and evaluation of a common elements intervention delivered by community mental health specialists, named "My Pathway to Healing." The study includes a pilot trial and CAB discussions to inform our understanding of the feasibility of scaling up the intervention.

The investigators randomized some participants to receive the interventions and some to receive control case manager visits, to pilot what a future effectiveness RCT might be. This intervention integrates psychoeducation, relaxation techniques, problem solving and cognitive coping, and addresses safety (when identified as a problem area). The intervention used in the intervention arm of our study has been developed for the specific context and culture of White Mountain Apache.

Those randomized into the My Pathway to Healing group will receive 4-8 hour-long sessions with a community mental health specialist, taking place over 8-12 weeks. The exact number of sessions will depend on presentation and symptom level using a stepped care approach where participants receive only what they need, but the provider can provide additional sessions if needed (i.e., increased element dosage; additional optional elements for specific issues). Those randomized into the control will continue to receive the standard case management via the Apache surveillance system. These control participants will be offered the My Pathway to Healing Program upon completion of the study.

Participants will be asked to partake in 5 study assessments. For intervention participants these assessments will take place at: baseline, after their last intervention session (endline; approximately 8-12 weeks post-baseline) and 4, 8, and 12 weeks post-endline. For control participants, these assessments will take place at: baseline, 8-12 weeks post-baseline (the maximum time the intervention would last; will be referred to as an endline) and 4, 8 and 12 weeks post-endline. These assessment visits will be conducted by Research Program Assistants. Assessments will take approximately 45-90 minutes to complete. In the feasibility study, assessments are not being statistically analyzed.

02

Conditions studied

  • Suicide; Trauma
  • Binge Drinking

Browse trials for

03

In context

Suicide Unverified

607 studies on the registry are indexed under Suicide; 162 are open to participants now.

This study's enrollment of 36 is below the median of 104 across 490 interventional studies indexed under Suicide.

Browse Suicide studies →

Lead sponsor

Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 371 studies on the registry; 42 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Compared within Suicide, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 25-65
  • Suicide ideation, suicide attempt, self-injurious behavior, and/or binge alcohol and/or drug use within past 90 days confirmed by the Apache suicide surveillance system
  • Experienced at least 2 adverse childhood experiences
  • Native American
  • Reside on or near the Fort Apache Indian Reservation.
  • An average score of 1 or above on a measure of symptoms of posttraumatic stress

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Have a serious developmental disorder
  • Have active psychosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Sessions with a community mental health specialist

    Those randomized into the intervention group will receive 4-8 hour-long sessions with a community mental health specialist, taking place over approximately 12 weeks. The common elements treatment approach intervention (called "My Pathway to Healing") includes psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping. The exact number of sessions delivered will depend on presentation and symptom level using a stepped care approach where participants receive only what they need, but the provider can provide additional sessions if needed (i.e., increased element dosage; additional optional elements for specific issues).

    Behavioral: Common Elements Treatment Approach

  • Active comparator
    Case management

    This study employs a randomized control design in which participants in the control group will receive case management and offered the intervention upon completion of their enrollment period.

    Behavioral: Common Elements Treatment Approach

Interventions

  • BehavioralCommon Elements Treatment Approach

    The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.

06

What researchers measure

Primary outcomes

  1. Number of Participants Completing Visits

    Feasibility as assessed by the number of participants completing sessions; 0, 0% reflects lowest feasibility, 100% reflects highest feasibility.

    Time frame: Up to 12 weeks post-baseline

  2. Number of People Approached Who Consented or Declined

    This timepoint is pre-randomization. 68 potential participants were approached to join the study; feasible if those who decline participation is less than 20%, a lower decline percentage indicates greater feasibility. A higher consent percentage indicates greater feasibility.

    Time frame: At consent

07

Results

Posted Apr 24, 2025
Limitations and caveats
Investigators received sponsor approval to transition the randomized control trial to a feasibility study with smaller sample size. Investigators aimed to recruit 30 participants and understand the feasibility of scaling this study at a larger size and understand the challenges of implementing this intervention with this population of adults experiencing suicide, self-injury, and substance use. The rest of the study design, aside from the sample size, remained the same throughout the project.

Participant flow

Participant flow — Overall Study
MilestoneSessions With a Community Mental Health SpecialistCase Management
Started1516
Completed711
Not completed85
Withdrew: Lost to follow-up85

Outcome measures

PrimaryNumber of Participants Completing Visits

Feasibility as assessed by the number of participants completing sessions; 0, 0% reflects lowest feasibility, 100% reflects highest feasibility.

Time frame:
Up to 12 weeks post-baseline
Reported as:
Count of participants · Participants
Number of Participants Completing Visits
ParticipantsSessions With a Community Mental Health SpecialistCase Management
Number of Participants Completing Visits711
PrimaryNumber of People Approached Who Consented or Declined

This timepoint is pre-randomization. 68 potential participants were approached to join the study; feasible if those who decline participation is less than 20%, a lower decline percentage indicates greater feasibility. A higher consent percentage indicates greater feasibility.

Time frame:
At consent
Reported as:
Count of participants · Participants
Number of People Approached Who Consented or Declined
ParticipantsDeclinedConsented
Number of People Approached Who Consented or Declined3236

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sessions With a Community Mental Health Specialist1/15 (6.7%)0/15 (0%)1/15 (6.7%)
Case Management0/16 (0%)0/16 (0%)2/16 (12.5%)
Most frequent other events
Most frequent other events
EventSessions With a Community Mental Health SpecialistCase Management
Binge substance useSocial circumstances0/152/16
Suicide ideationPsychiatric disorders1/150/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sessions With a Community Mental Health SpecialistCase ManagementTotal
<=18 years000
Between 18 and 65 years151631
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Sessions With a Community Mental Health SpecialistCase ManagementTotal
Female7411
Male81220
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sessions With a Community Mental Health SpecialistCase ManagementTotal
American Indian or Alaska Native151631
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Sessions With a Community Mental Health SpecialistCase ManagementTotal
United States151631
Index event behavior
Index event behavior(Participants)Sessions With a Community Mental Health SpecialistCase ManagementTotal
Binge substance use5813
Self-injury112
Suicide ideation7613
Suicide attempt213
08

Study locations

1 site
  • Johns Hopkins Center for American Indian Health Whiteriver Office
    Whiteriver, Arizona 85941, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data collected as part of this project is protected by tribal sovereignty. Any requests for data sharing must be approved by all relevant tribal authorities (tribal council, health board, etc.) before data can be shared.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04585906
Collaborators
Native American Research Center for Health, National Institute of General Medical Sciences (NIGMS)
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Jul 19, 2022
Primary completion
Mar 28, 2024
Completion
Nov 12, 2024
Results posted
Apr 24, 2025
Last update
Apr 24, 2025

Study contacts

Emily Haroz, PhD
principal investigator · Johns Hopkins Bloomberg School of Public Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion